Molecular Targets of FTY720 (Fingolimod)

Author(s): M.R. Pitman, J.M. Woodcock, A.F. Lopez, S.M. Pitson.

Journal Name: Current Molecular Medicine

Volume 12 , Issue 10 , 2012

Abstract:

FTY720 is a recently approved first line therapy for relapsing forms of multiple sclerosis. In this context, FTY720 is a pro-drug, with its anti-multiple sclerosis, immunosuppressive effects largely elicited following its phosphorylation by sphingosine kinase 2 and subsequent modulation of G protein-coupled sphingosine 1-phosphate (S1P) receptor 1 that induces lymphopenia by altering lymphocyte trafficking. A number of other biological effects of FTY720 have, however, been described, including considerable evidence that this drug also has anti-cancer properties. These other effects of FTY720 are independent of S1P receptors, and appear facilitated by modulation of a range of other recently described protein targets by nonphosphorylated FTY720. Here, we review the direct targets of FTY720 that contribute to its anti-cancer properties. We also discuss other recently described protein effectors that, in combination with S1P receptors, appear to contribute to its immunosuppressive effects.

Keywords: Apoptosis, cancer, FTY720, fingolimod, lymphopenia, lysophospholipid, sphingosine, sphingosine 1-phosphate, therapeutic drug, Gilenya™, myriocin, immunosuppressive activity, immuno-suppressants, toxicity, multiple sclerosis

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 10
Year: 2012
Page: [1207 - 1219]
Pages: 13
DOI: 10.2174/156652412803833599
Price: $58

Article Metrics

PDF: 50